Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Mind Medicine price target lowered to $18 from $22 at Canaccord » 07:51
11/21/22
11/21
07:51
11/21/22
07:51
MNMD

Mind Medicine

$2.70 /

-0.055 (-2.00%)

Canaccord analyst Tania…

Canaccord analyst Tania Armstrong-Whitworth lowered the firm's price target on Mind Medicine to $18 from $22 and keeps a Speculative Buy rating on the shares. The analyst said given ongoing capital constraints among biotechnology peers and considering their recent cost-cutting efforts, she has reduced her target.

ShowHide Related Items >><<
MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

11/16/22 RBC Capital
Mind Medicine initiated with an Outperform at RBC Capital
11/14/22 Maxim
Mind Medicine price target lowered to $8 from $22.50 at Maxim
10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

  • 28
    Sep
MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

Options
Largest borrow rate increases among liquid names » 08:45
11/18/22
11/18
08:45
11/18/22
08:45
PHUN

Phunware

$1.21 /

-0.06 (-4.74%)

, NKLA

Nikola

$2.89 /

-0.11 (-3.67%)

, MNMD

Mind Medicine

$2.75 /

-0.19 (-6.46%)

, QS

QuantumScape

$7.15 /

-0.27 (-3.64%)

, KOLD

ProShares UltraShort Bloomberg Natural Gas

$15.46 /

-0.79 (-4.86%)

, AVDL

Avadel Pharmaceuticals

$7.14 /

-0.47 (-6.18%)

, PTLO

Portillo's

$20.47 /

-0.855 (-4.01%)

, QSR

Restaurant Brands

$66.61 /

+2.84 (+4.45%)

, SKLZ

Skillz

$1.02 /

-0.05 (-4.69%)

, EWH

MSCI Hong Kong Index

$19.78 /

+0.215 (+1.10%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Phunware (PHUN) 17.26% +1.39, Nikola (NKLA) 45.43% +0.82, MindMed (MNMD) 4.64% +0.82, Quantumscape (QS) 6.65% +0.73, ProShares UltraShort DJ-UBS Natural Gas (KOLD) 6.97% +0.40, Avadel Pharmaceuticals (AVDL) 5.78% +0.23, Portillo's (PTLO) 1.90% +0.21, Restaurant Brands (QSR) 0.44% +0.19, Skillz (SKLZ) 1.22% +0.18, and iShares Hong Kong (EWH) 5.21% +0.14.

ShowHide Related Items >><<
SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

QS QuantumScape
$7.15 /

-0.27 (-3.64%)

PTLO Portillo's
$20.47 /

-0.855 (-4.01%)

PHUN Phunware
$1.21 /

-0.06 (-4.74%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

KOLD ProShares UltraShort Bloomberg Natural Gas
$15.46 /

-0.79 (-4.86%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

PHUN Phunware
$1.21 /

-0.06 (-4.74%)

12/28/21 Roth Capital
Roth Capital keeps Buy rating on Phunware, lowers price target to $4
NKLA Nikola
$2.89 /

-0.11 (-3.67%)

11/04/22 Cowen
Nikola price target lowered to $10 from $12.50 at Cowen
11/04/22 Wedbush
Nikola price target lowered to $6 from $10 at Wedbush
09/23/22 Northland
Alta Equipment Group initiated with an Outperform at Northland
09/14/22 BTIG
Nikola upgraded to Buy from Neutral at BTIG
MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

11/16/22 RBC Capital
Mind Medicine initiated with an Outperform at RBC Capital
11/14/22 Maxim
Mind Medicine price target lowered to $8 from $22.50 at Maxim
10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
QS QuantumScape
$7.15 /

-0.27 (-3.64%)

11/09/22 Morgan Stanley
Morgan Stanley cuts QuantumScape to Underweight after 'narrative changing' Q3
11/09/22 Morgan Stanley
QuantumScape downgraded to Underweight from Equal Weight at Morgan Stanley
09/28/22 Truist
Truist starts QuantumScape at Hold, upside limited as large volumes years away
09/28/22 Truist
QuantumScape initiated with a Hold at Truist
KOLD ProShares UltraShort Bloomberg Natural Gas
$15.46 /

-0.79 (-4.86%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

08/11/22 SVB Securities
Avadel Pharmaceuticals price target raised to $12 from $6 at SVB Securities
08/10/22 Jefferies
Jefferies cuts Avadel to Hold while awaiting Lumryz full approval
08/09/22 Jefferies
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
PTLO Portillo's
$20.47 /

-0.855 (-4.01%)

09/29/22 Deutsche Bank
Portillo's initiated with a Hold at Deutsche Bank
08/05/22 Baird
Portillo's price target raised to $30 from $22 at Baird
08/05/22 Piper Sandler
Portillo's price target raised to $27 from $23 at Piper Sandler
06/28/22 Morgan Stanley
Portillo's initiated with an Equal Weight at Morgan Stanley
QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

11/04/22 Goldman Sachs
Restaurant Brands upgraded to Neutral from Sell at Goldman Sachs
10/20/22 Barclays
Restaurant Brands price target lowered to $65 from $68 at Barclays
10/12/22 Deutsche Bank
Restaurant Brands price target lowered to $68 from $70 at Deutsche Bank
10/10/22 OTR Global
Restaurant Brands view upgraded to Positive from Mixed at OTR Global
SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

10/12/22 Citi
Skillz price target lowered to 95c from $1.50 at Citi
10/12/22 BTIG
Skillz downgraded to Sell from Neutral at BTIG
08/31/22 Citi
Skillz price target lowered to $1.50 from $1.55 at Citi
08/04/22 Canaccord
Skillz downgraded to Hold on 'disappointing' results at Canaccord
EWH MSCI Hong Kong Index
$19.78 /

+0.215 (+1.10%)

SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

QS QuantumScape
$7.15 /

-0.27 (-3.64%)

PTLO Portillo's
$20.47 /

-0.855 (-4.01%)

PHUN Phunware
$1.21 /

-0.06 (-4.74%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

  • 15
    Nov
  • 28
    Sep
  • 12
    Aug
QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

QS QuantumScape
$7.15 /

-0.27 (-3.64%)

PTLO Portillo's
$20.47 /

-0.855 (-4.01%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

QS QuantumScape
$7.15 /

-0.27 (-3.64%)

PHUN Phunware
$1.21 /

-0.06 (-4.74%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

KOLD ProShares UltraShort Bloomberg Natural Gas
$15.46 /

-0.79 (-4.86%)

EWH MSCI Hong Kong Index
$19.78 /

+0.215 (+1.10%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

Initiation
Mind Medicine initiated with an Outperform at RBC Capital » 06:40
11/16/22
11/16
06:40
11/16/22
06:40
MNMD

Mind Medicine

$2.85 /

+0.02 (+0.71%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams initiated coverage of Mind Medicine with an Outperform rating and $5 price target. The analyst states that psychedelics, including LSD - which Mind Medicine lead drug MM-120 is a formulation of - have "shown increasing potential of late in treating mental health disorders". Abrahams adds that the company is taking a prudent and thoughtful approach to clinical development and scale-up that should maximize the potential they can capitalize on early promise shown for LSD in the high unmet need generalized anxiety disorder indication.

ShowHide Related Items >><<
MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

11/14/22 Maxim
Mind Medicine price target lowered to $8 from $22.50 at Maxim
10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

  • 28
    Sep
MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

Recommendations
Mind Medicine price target lowered to $8 from $22.50 at Maxim » 08:32
11/14/22
11/14
08:32
11/14/22
08:32
MNMD

Mind Medicine

$2.88 /

+0.29 (+11.20%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy lowered the firm's price target on Mind Medicine to $8 from $22.50 but keeps a Buy rating on the shares. The analyst is citing the company's equity financing and dilution in reducing his price target, though he also notes that it has significantly strengthened balance sheet to reach clinical milestones on its refocused pipeline. McCarthy further notes that Mind Medicine's lead program, MM-120 in generalized anxiety disorder, is expected to report data in late 2023, and its second MM-120 program, low dose for ADHD, is also expected to report topline data in the second half of next year.

ShowHide Related Items >><<
MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

  • 28
    Sep
MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

Earnings
Mind Medicine reports Q3 EPS (56c), consensus (60c) » 08:07
11/10/22
11/10
08:07
11/10/22
08:07
MNMD

Mind Medicine

$2.40 /

-0.175 (-6.80%)

Cash and cash equivalents…

Cash and cash equivalents of $154.5M are expected to fund current operating plan into first half of 2025. "We are pleased with the progress made in the third quarter as we continue executing on our core development programs, MM-120 and MM-402, and accelerating preparations for Phase 3 studies - all with the goal of bringing our treatments to market as efficiently as possible for the benefit of both patients and shareholders. During the quarter, we initiated enrollment in the largest well-controlled clinical trial of LSD, a 200-patient Phase 2b trial in patients diagnosed with Generalized Anxiety Disorder. We expect a readout of that data in the late half of 2023. Additionally, we continue our efforts to bring MM-402 into human clinical studies," said CEO Robert Barrow. "Throughout Q3, we have taken meaningful steps to reduce our cash expenditures and we further bolstered our balance sheet by raising approximately $60 million. We believe our strong financial position provides the Company with necessary funding to prepare for later stage clinical development of MM-120 while continuing our pursuit to retain, protect, and build the company's intellectual property portfolio."

ShowHide Related Items >><<
MNMD Mind Medicine
$2.40 /

-0.175 (-6.80%)

MNMD Mind Medicine
$2.40 /

-0.175 (-6.80%)

10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
MNMD Mind Medicine
$2.40 /

-0.175 (-6.80%)

  • 28
    Sep
MNMD Mind Medicine
$2.40 /

-0.175 (-6.80%)

MNMD Mind Medicine
$2.40 /

-0.175 (-6.80%)

MNMD Mind Medicine
$2.40 /

-0.175 (-6.80%)

Hot Stocks
Mind Medicine investor demands investigation into misconduct allegations » 08:38
11/03/22
11/03
08:38
11/03/22
08:38
MNMD

Mind Medicine

$2.78 /

-0.18 (-6.09%)

FCM MM HOLDINGS notifies…

FCM MM HOLDINGS notifies shareholders that it has formally filed a complaint with the Securities and Exchange Commission and will file a referral to the Department of Justice regarding allegations against Mind Medicine. The Complaint focuses on the following allegations: self-dealing, lack of material disclosure, false statements/public statement fraud, and if the allegations are true, criminal activities, by CEO Robert Barrow, under Sarbanes-Oxley. The Complaint presents and analyses the allegations in the lawsuit Freeman v. Burbank et al. that MindMed's intellectual property was mishandled due to a one-sided deal negotiated by Mr. Stephen Hurst, then MindMed's CEO, and Mr. Carey Turnbull, CEO of Ceruvia Lifesciences. Mr. Hurst founded Ceruvia's predecessor, purportedly in secret. If the Deal occurred, Ceruvia has undisclosed freedom to operate on MindMed's IP surrounding LSD and its derivatives, and MindMed is not able to research or compete on BOL-148. The Complaint also lists Ceruvia executives who concurrently worked for MindMed during Messrs. Hurst and Barrow's tenure and the implications for MindMed's IP and trade secrets. Additionally, the Complaint scrutinizes whether MindMed adequately disclosed to investors the significant risk of MM-110's failure in gaining full Food and Drug Administration product approval. After MindMed terminated the MM-110 program in August of 2022, FCM conducted a rigorous review of publicly available data of MM-110, a core drug of MindMed, from primarily both MM-110's patent application and protocol of the Phase I trial, which were available prior to the initiation the Study. The Complaint addresses FCM's conclusion that it is highly unlikely the FDA would have allowed the Study to be performed in the US as written - i.e. patients would be treated at a dose thirty-five times higher than the comparable dose which caused death in mice. Ultimately, MindMed instead performed the Study in Australia, and in May 2022, reported that the Study's topline results were favorable regarding safety and tolerability and builds on "encouraging" results from pre-clinical studies. The Results were then presented to the FDA, and MindMed later disclosed that the FDA now requires MindMed to complete a myriad of pre-clinical safety studies prior to instituting additional clinical trials in the US. Mr. Barrow stated that the Pre-Clinical Studies could take years, and MindMed subsequently shuttered the program. The Complaint also examines the departures of several high-profile executives of the Company right before they were required to sign off on MindMed's SEC filings. Similar to Chief Legal Officer Cynthia Hu who left one month prior to being required to sign MindMed's stock offering, Chief Financial Officer David Guebert resigned from MindMed the business day before he was obligated to make his first Sarbanes-Oxley certification of MindMed's financials. The Complaint further notes that MindMed's auditor Ernst & Young was fired shortly after reporting that MindMed had a material weakness in its internal controls under Sarbanes-Oxley.

ShowHide Related Items >><<
MNMD Mind Medicine
$2.78 /

-0.18 (-6.09%)

MNMD Mind Medicine
$2.78 /

-0.18 (-6.09%)

10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
MNMD Mind Medicine
$2.78 /

-0.18 (-6.09%)

  • 28
    Sep
MNMD Mind Medicine
$2.78 /

-0.18 (-6.09%)

MNMD Mind Medicine
$2.78 /

-0.18 (-6.09%)

MNMD Mind Medicine
$2.78 /

-0.18 (-6.09%)

Over a month ago
Conference/Events
Mind Medicine to participate in a conference call with Roth Capital » 11:45
10/18/22
10/18
11:45
10/18/22
11:45
MNMD

Mind Medicine

$3.13 /

+0.27 (+9.46%)

Biotech Analyst Piros…

Biotech Analyst Piros holds a conference call with CEO Barrow on October 18 at 12 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
MNMD Mind Medicine
$3.13 /

+0.27 (+9.46%)

MNMD Mind Medicine
$3.13 /

+0.27 (+9.46%)

10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
MNMD Mind Medicine
$3.13 /

+0.27 (+9.46%)

  • 28
    Sep
MNMD Mind Medicine
$3.13 /

+0.27 (+9.46%)

MNMD Mind Medicine
$3.13 /

+0.27 (+9.46%)

MNMD Mind Medicine
$3.13 /

+0.27 (+9.46%)

Conference/Events
Mind Medicine to participate in a conference call with Roth Capital » 04:55
10/18/22
10/18
04:55
10/18/22
04:55
MNMD

Mind Medicine

$2.86 /

-0.03 (-1.04%)

Biotech Analyst Piros…

Biotech Analyst Piros holds a conference call with CEO Barrow on October 18 at 12 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
MNMD Mind Medicine
$2.86 /

-0.03 (-1.04%)

MNMD Mind Medicine
$2.86 /

-0.03 (-1.04%)

10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
MNMD Mind Medicine
$2.86 /

-0.03 (-1.04%)

  • 28
    Sep
MNMD Mind Medicine
$2.86 /

-0.03 (-1.04%)

MNMD Mind Medicine
$2.86 /

-0.03 (-1.04%)

MNMD Mind Medicine
$2.86 /

-0.03 (-1.04%)

Conference/Events
Mind Medicine to participate in a conference call with Roth Capital » 15:02
10/17/22
10/17
15:02
10/17/22
15:02
MNMD

Mind Medicine

$2.87 /

-0.015 (-0.52%)

Biotech Analyst Piros…

Biotech Analyst Piros holds a conference call with CEO Barrow on October 18 at 12 pm hosted by Roth Capital. Webcast Link

ShowHide Related Items >><<
MNMD Mind Medicine
$2.87 /

-0.015 (-0.52%)

MNMD Mind Medicine
$2.87 /

-0.015 (-0.52%)

10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
MNMD Mind Medicine
$2.87 /

-0.015 (-0.52%)

  • 28
    Sep
MNMD Mind Medicine
$2.87 /

-0.015 (-0.52%)

MNMD Mind Medicine
$2.87 /

-0.015 (-0.52%)

MNMD Mind Medicine
$2.87 /

-0.015 (-0.52%)

Recommendations
Mind Medicine price target lowered to US$22 from C$60 at Canaccord » 07:34
10/04/22
10/04
07:34
10/04/22
07:34
MNMD

Mind Medicine

$3.32 /

-0.175 (-5.01%)

Canaccord analyst Tania…

Canaccord analyst Tania Armstrong-Whitworth lowered the firm's price target on Mind Medicine to US$22 from C$60 and keeps a Speculative Buy rating on the shares after the company closed its previously announced $30M equity offering. The analyst said the offering proceeds will be used to fund its ongoing development programs, working capital, general corporate expenses, and potentially to invest in or acquire complementary businesses and/or technologies and that the added cash buffer takes its liquidity to fund operations to the first quarter of 2025. Though she can think of a few reasons why management "felt pressured to put up such a punitive deal so far in advance of running out of cash," Armstrong-Whitworth added that she believes the deal was "poorly timed and ill-conceived."

ShowHide Related Items >><<
MNMD Mind Medicine
$3.32 /

-0.175 (-5.01%)

MNMD Mind Medicine
$3.32 /

-0.175 (-5.01%)

09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
MNMD Mind Medicine
$3.32 /

-0.175 (-5.01%)

  • 28
    Sep
MNMD Mind Medicine
$3.32 /

-0.175 (-5.01%)

MNMD Mind Medicine
$3.32 /

-0.175 (-5.01%)

MNMD Mind Medicine
$3.32 /

-0.175 (-5.01%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.